Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 18/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590012 | 0.82 | GRIN2B (0.53) | GRIN2BGRIN1CYP2C9KCNH2CYP2C19 | |
| SCHEMBL16897887 | 0.80 | KMT2A (0.52) | KCNH2CYP2C19 | |
| SCHEMBL3605111 | 0.74 | KMT2A (0.44) | GRIN2BCYP2C9CYP2C19 | |
| SCHEMBL1017851 | 0.72 | MEN1 (0.49) | KCNH2 | |
| SCHEMBL3605733 | 0.72 | ALDH1A1 (0.48) | GRIN2BHTR7 | |
| SCHEMBL3598861 | 0.72 | ALDH1A1 (0.47) | GRIN2BCYP2C9CYP2C19HTR7 | |
| SCHEMBL3601858 | 0.70 | KDM4E (0.48) | GRIN2B | |
| SCHEMBL18363221 | 0.70 | GRIN2B (1.00) | GRIN2BGRIN1CYP2C9KCNH2CYP2C19 | |
| SCHEMBL18363210 | 0.70 | GRIN2B (1.00) | GRIN2BGRIN1CYP2C9KCNH2CYP2C19 | |
| SCHEMBL3605190 | 0.70 | KMT2A (0.49) | GRIN2BCYP2C19HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | GRIN2B 2950/4885GRIN1 2761/4885CYP2C9 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.